Y. Xiang , K. Hasegawa , H. Zhu , Q. Zhou , X. Zhang , J-Y. Lee , T. Usami , W. Zhao , E. Tharavichitkul , S. Suzuki , T-C. Chang , G.N. Zhang , C-L. Chang , A-A. Lertkhachonsuk , B-G. Kim , K. Li , K.U. Yamada , S. Toker , D. Lorusso
{"title":"23O 一项针对高危局部晚期宫颈癌患者的化放疗联合或不联合 pembrolizumab 的随机 III 期双盲研究(KEYNOTE-A18/ENGOT-cx11/GOG-3047):亚洲入组患者的研究结果","authors":"Y. Xiang , K. Hasegawa , H. Zhu , Q. Zhou , X. Zhang , J-Y. Lee , T. Usami , W. Zhao , E. Tharavichitkul , S. Suzuki , T-C. Chang , G.N. Zhang , C-L. Chang , A-A. Lertkhachonsuk , B-G. Kim , K. Li , K.U. Yamada , S. Toker , D. Lorusso","doi":"10.1016/j.esmoop.2024.103523","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012924/pdfft?md5=c2e007b99e4d946ef11c3e74303871d6&pid=1-s2.0-S2059702924012924-main.pdf","citationCount":"0","resultStr":"{\"title\":\"23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia\",\"authors\":\"Y. Xiang , K. Hasegawa , H. Zhu , Q. Zhou , X. Zhang , J-Y. Lee , T. Usami , W. Zhao , E. Tharavichitkul , S. Suzuki , T-C. Chang , G.N. Zhang , C-L. Chang , A-A. Lertkhachonsuk , B-G. Kim , K. Li , K.U. Yamada , S. Toker , D. Lorusso\",\"doi\":\"10.1016/j.esmoop.2024.103523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2059702924012924/pdfft?md5=c2e007b99e4d946ef11c3e74303871d6&pid=1-s2.0-S2059702924012924-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702924012924\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702924012924","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia
期刊介绍:
ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research.
ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO.
Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.